1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Alcon Inc.

Alcon Inc.

ALC.SW
Alcon Inc.CH flagSwiss Exchange
54.94
CHF
-0.10
- -
26.78BMarket Cap
Alcon Inc.
ALC.SW
(Swiss Exchange)

Recent

price

54.94

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
13.5
13.9
14.64
15.38
13.97
16.92
17.74
19.18
20.05
21.09
21.65
Revenue per Share
-0.35
0.52
-0.46
-1.34
-1.09
0.77
0.68
1.98
2.06
1.99
1.67
Basic EPS, GAAP
1.51
1.48
0.88
0.5
0.52
0.34
0.96
1.09
2.85
3.26
3.24
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
0.11
0.2
0.24
0.26
0.34
- -
Dividend per Share
- -
46.94
46.32
0.04
0.04
0.04
0.04
0.04
0.04
- -
0.04
Book Value per Share
- -
5.31
6.26
0.34
1.68
3.24
2.16
5.35
8.13
- -
8.14
Tangible Book Value per Share
489
489
489
488
489
490
491
493
494
493
491
Basic Weighted Avg Shares
6,596
6,792
7,153
7,508
6,833
8,291
8,717
9,455
9,911
10,401
10,634
Sales/Revenue/Turnover
0.15
-1.13
-3.47
-2.49
-7.05
7
7.71
10.99
14.26
13.08
11.13
Operating Margin (%)
1,289
1,305
1,622
1,425
1,623
1,219
1,123
1,221
1,228
1,335
1,347
Depreciation Expense
-170
256
-227
-656
-531
376
335
974
1,018
980
819
Net Income, GAAP
- -
- -
- -
- -
- -
10.05
27.65
- -
18.95
15.52
16.94
Effective Tax Rate (%)
-2.58
3.77
-3.17
-8.74
-7.77
4.54
3.84
10.3
10.27
9.42
7.7
Profit Margin (%)
- -
1,509
1,506
1,936
2,729
2,914
2,455
3,249
4,031
3,400
3,616
Working Capital
- -
84
89
3,498
4,264
4,305
4,900
5,011
429
429
4,605
LT Debt
- -
23,029
22,639
19,303
18,822
19,256
19,677
20,624
21,553
- -
22,133
Total Equity
- -
- -
- -
- -
- -
2.2
1.99
- -
4.75
10.14
3.58
Return on Invested Capital (%)
- -
- -
- -
- -
- -
10.75
9.01
- -
40.66
219.91
18.85
Return on Capital (%)
- -
2.23
-1
-5.79
-2,655
1,880
1,675
4,870
5,090
9,800
4,095
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
647
- -
648
LT Borrowings
4,163
- -
4,157
LT Finance Leases
428
429
448
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
491
487
488
Market Capitalization
36,795
39,399
36,424

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
6,333
6,449
6,620
Cash, Cash Equivalents & STI
1,498
- -
1,659
Accounts Receivable, Net
1,908
- -
1,981
Inventories
2,433
2,391
2,438
Total Current Liabilities
2,990
3,049
3,004
Payables & Accruals
1,091
- -
1,127
ST Debt
647
- -
648
Deferred Revenue
- -
84
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
68.12%
14.29%
Net Income, GAAP
- -
1.97%
-3.73%
Sales/Revenue/Turnover
- -
8.94%
4.94%
Total Cash Common Dividend
- -
- -
27.69%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,459
2,496
2,454
2,502
9,911
2025
2,473
2,596
2,614
2,718
10,401
2026
2,706
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.5
0.45
0.53
0.57
2.06
2025
0.71
0.36
0.48
0.44
1.99
2026
0.39
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.26
2025
- -
- -
- -
- -
0.34
2026
- -
- -
- -
- -
- -
Similar Companies
Sysmex Corporation (6869.T)
AngioDynamics, Inc. (ANGO)
Shanghai Kindly Medical Instruments Co., Ltd. (1501.HK)
AVE Science&Technology CO.,LTD (688067.SS)
Signature Eyewear, Inc. (SEYE)
Angelalign Technology Inc. (6699.HK)
Business
Alcon Inc. (ALC.SW) researches, develops, manufactures, distributes and sells eye care products worldwide, operating in two primary segments, Surgical and Vision Care; the Surgical segment provides equipment, instrumentation and diagnostics such as the Centurion vision system and LenSx laser system, intraocular lenses including PanOptix, Vivity and AcrySof IQ, other implantables, consumables like viscoelastics, surgical solutions, incisional instruments and custom packs for cataract, vitreoretinal and refractive surgeries; the Vision Care segment offers daily disposable, reusable and color-enhancing contact lenses under brands like Dailies, Total1, Precision1 and Air Optix, plus ocular health products including Systane dry eye drops, Pataday allergy relief, contact lens care solutions, ocular vitamins and redness relievers. Founded in 1945 in Fort Worth, Texas, by pharmacists Robert Alexander and William Conner, the company is incorporated in Fribourg, Switzerland, with global headquarters in Geneva and a major operational hub in Fort Worth; it employs over 25,000 associates, operates in 60 countries and serves patients in more than 140 countries. In recent developments, Alcon acquired a majority interest in Aurion Biotech in March 2025 to advance cell therapy AURN001 for corneal endothelial disease into Phase 3 trials, agreed to acquire LENSAR in March 2025 for its ALLY Robotic Cataract Laser System and Streamline software to bolster femtosecond laser-assisted cataract surgery, entered a definitive agreement in August 2025 to purchase STAAR Surgical for approximately $1.5 billion to add EVO implantable collamer lenses for myopia correction, and plans to acquire LumiThera for its photobiomodulation device targeting dry age-related macular degeneration, with most transactions expected to close in mid-to-late 2025.

Company News

APIChatGPT

  • globenewswire.com

    Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs